pentobarbital will minimize the extent or impact of imatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
pentobarbital and olopatadine intranasal each increase sedation. Stay away from or Use Alternate Drug. Coadministration boosts risk of CNS despair, which can result in additive impairment of psychomotor general performance and result in daytime impairment.
pentobarbital increases toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. CYP3A4 inducers may possibly boost the metabolism of ifosfamide to its Energetic alkylating metabolites.
Reserve concomitant prescribing of these drugs in individuals for whom other therapy options are inadequate. Restrict dosages and durations on the minimum demanded. Keep an eye on closely for signs of respiratory depression and sedation.
Continually check important signals in the course of sedation and recovery interval if coadministered. Thoroughly titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
pentobarbital will minimize the level or effect of triamcinolone acetonide injectable suspension by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will decrease the extent or result of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will minimize the extent or result of parecoxib by click here influencing hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.
buprenorphine, prolonged-performing injection and pentobarbital both boost sedation. Stay away from or Use Alternate Drug. Restrict use to individuals for whom alternate treatment alternatives are insufficient
pentobarbital decreases effects of hemin by pharmacodynamic antagonism. Use Caution/Keep an eye on. Drugs that raise delta-aminolevulinic acid synthetase may perhaps minimize hemin influence.
Contraindicated. Coadministration of lorlatinib with robust CYP3A inducers is contraindicated. Discontinue the powerful CYP3A inducer for three plasma half-lives prior to initiating lorlatinib.
pentobarbital will reduce the extent or outcome of paclitaxel protein bound by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Mysterious.
With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the level or outcome of mifepristone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. CYP3A4 inducers have not been analyzed, coadministration not advisable by manufacturer